-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q2 2025.
- InMed Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$1.79M, a 7.71% increase year-over-year.
- InMed Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$8.16M, a 6.34% decline year-over-year.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2025 was -$8.16M, a 6.34% decline from 2024.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$7.68M, a 3.42% increase from 2023.
- InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.95M, a 57.3% increase from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)